Testing a new immune cell therapy for hard-to-treat blood cancer

This trial is testing FL-33 CAR T therapy, a new type of cancer treatment that uses your own immune cells (or cells from a donor) engineered to recognize and attack leukemia cells. The study will enroll up to 27 patients with acute myeloid leukemia that has either not responded to standard chemotherapy or has come back after treatment. Researchers will test different doses of this medication to find the safest and most effective amount, and will monitor you for side effects and how well the treatment works.

Acute myeloid leukemia that resists standard chemotherapy or comes back after treatment is very difficult to manage, and many patients have limited options. This medication represents a new approach—teaching the immune system to directly target leukemia cells—to help patients who have run out of other treatment choices.